RESEARCH MONOGRAPH · KDC-MN-346

Sodium Oxybate (GHB)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

65/100

Two-receptor system with a narrow therapeutic window and the most underrated slow-wave sleep effect in pharmacology

GHB is one of those compounds where the reputation precedes the pharmacology, which is a shame because the pharmacology is genuinely interesting. Endogenous metabolite of GABA, low micromolar affinity for its own GHB receptors plus partial agonism at GABA-B at higher concentrations. The receptor split matters because the dose-response curve is biphasic in ways that complicate everything.

What's clinically interesting is what GHB does to slow-wave sleep. At narcolepsy doses, you see a near-doubling of N3 sleep and a sharp suppression of REM, which is exactly opposite to what most GABA-A modulators do. The growth hormone surge during early-night N3 is real and reproducible. Whether that GH bump matters functionally is a separate question, but the sleep architecture effect is striking.

The mechanism work coming out of the Crunelli group (thalamocortical), the Maitre group (GHB receptor cloning attempts) and the Bay group has been slow but informative. The fact that we still dont have a fully cloned, characterized GHB receptor decades after its endogenous identity was confirmed is honestly embarrassing for the field.

What we dont like is the steep dose-response. The window between effective hypnotic dose and severe respiratory depression in opioid-naive subjects is narrow, and combined with anything else CNS depressant (especially alcohol) it gets dangerous fast. This is genuinely one of the trickier pharmacology profiles to dose, which is why even the clinical product (Xyrem) has the REMS program it does.

For research purposes, GHB and its prodrug GBL are useful tools for studying GABA-B mediated absence seizure models, thalamic oscillations, and slow-wave sleep generation. The sodium salt is hygroscopic but stable, easy to dose in animal work, and the metabolism (back to succinic semialdehyde, into the TCA cycle) is unusually clean.

Sourcing is complicated by the controlled status in most jurisdictions, which is the real research-access bottleneck more than synthesis difficulty.

Honestly the most underappreciated angle here is GHB as a tool compound for slow-wave sleep neuroscience. People doing memory consolidation work, glymphatic clearance studies, or thalamocortical oscillation research could be using it more than they do. Reputation problem.

Evidence: 75
Mechanism: 65
Reliability: 78
Safety: 45
Sourcing: 55
Value: 65
Signal: 72
Staying power: 68

Plain-language summary Intrigue 64 / 100

Sodium oxybate is the prescription form of GHB, the same compound abused recreationally and notorious as a date-rape drug. As Xyrem (and the lower-sodium successor Xywav) it is FDA-approved for narcolepsy with cataplexy, where it consolidates deep slow-wave sleep and dramatically reduces cataplectic attacks. It is also approved in Europe for alcohol withdrawal and dependence, an indication never pursued in the US. The drug is taken in two doses (because the half-life is short) under a heavily restricted distribution program. Misuse causes profound respiratory depression, especially when combined with alcohol. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

GHB receptor agonist / GABA-B partial agonist

Sodium gamma-hydroxybutyrate; an endogenous neurotransmitter and prescription medication for narcolepsy and (controversially) alcoholism.

Abstract

Sodium oxybate (sodium 4-hydroxybutanoate, GHB; CAS 502-85-2; molecular formula C4H7NaO3; molecular weight 126.09) is the sodium salt of gamma-hydroxybutyrate, an endogenous short-chain fatty acid neurotransmitter and metabolite of GABA. The compound binds two distinct receptors: high-affinity GHB receptors (Kd approximately 50 nM, low capacity) and low-affinity GABA-B receptors (Ki approximately 5 mM, high capacity); pharmacologically meaningful effects at clinical doses are predominantly GABA-B-mediated. Approved indications: narcolepsy with cataplexy and excessive daytime sleepiness; clinical effect involves consolidation of slow-wave sleep. Used in some European countries (notably Italy, France) for alcohol withdrawal and dependence treatment. Schedule III when prescribed as Xyrem; Schedule I as illicit GHB. The narrow therapeutic index makes overdose easy and dangerous; recreational misuse with predatory drug-facilitated assault has been a significant public health issue. Plasma half-life is approximately 0.5 to 1 hour. Used as the canonical GHB receptor and GABA-B partial agonist in academic neuroscience.

Mechanism of action

Endogenous short-chain fatty acid neurotransmitter; high-affinity GHB receptor and low-affinity GABA-B receptor agonism. Consolidates slow-wave sleep.

Reported research dose ranges

Clinical 4.5 to 9 g in the published literature.

References

Snead OC 3rd, Gibson KM. gamma-Hydroxybutyric acid. N Engl J Med 2005.
Mamelak M. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Prog Neurobiol 2009.
Caputo F, et al. Pharmacological treatment of alcohol use disorder: an update. Eur Neuropsychopharmacol 2018.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-346

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Sodium Oxybate (GHB)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs